Cost-Volume-Profit Strategy Analysis: SLP 4 Product Portfolio
This paper analyzes a business simulation (SLP 4) in which a cost-volume-profit framework guides strategic decisions across three products: the X5, X6, and X7. The author evaluates each product's position in its life cycle, assigns R&D funding accordingly, and sets pricing to maximize cumulative profit over a four-year period (2012–2015). Key decisions include discontinuing the X5 after 2014, reallocating its R&D budget to the X6, and reducing the X7's price to stimulate demand. Results are compared against a prior simulation (SLP 2), revealing that the adjusted strategy improved total cumulative profitability from approximately $1.43 billion to $1.76 billion, while also highlighting the X7's untapped market potential as the primary growth opportunity going forward.
- Introduction and SLP 3 Context: SLP 3 underperformance motivates revised SLP 4 strategy
- X5: Pricing and R&D Strategy: X5 nearing end of life; cut R&D, lower price
- X6: Premium Product Strategy: X6 remains profitable; increase R&D allocation
- X7: Low-End Market Strategy: X7 overpriced; drop price to capture demand
- Summary Strategy Table: Consolidated price and R&D decisions by year
- Results and Comparative Performance: Unit sales, revenue, and profit outcomes by year
- Analysis and Strategic Implications: X7 identified as primary future growth opportunity
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper applies cost-volume-profit (CVP) logic consistently across all three products, anchoring each strategic recommendation in quantitative reasoning rather than intuition.
- Each product section follows a parallel structure — life cycle position, fixed cost analysis, pricing rationale, and R&D allocation — making the argument easy to follow and compare.
- The results section directly tests the paper's hypotheses by comparing outcomes to a prior simulation, giving the analysis an empirical feedback loop.
Key academic technique demonstrated
The paper demonstrates comparative scenario analysis: decisions made in SLP 4 are explicitly benchmarked against SLP 2 results, allowing the author to isolate the effect of individual variable changes (price, R&D, discontinuation timing) on profitability. This technique is common in managerial accounting and business strategy coursework.
Structure breakdown
The paper opens with a brief review of SLP 3 performance to motivate the new strategy, then devotes one section to each of the three products (X5, X6, X7), covering both rationale and recommended parameters. A strategy summary table consolidates the decisions before the paper transitions to reporting simulation results and interpreting them against prior benchmarks. The conclusion identifies the X7 as the critical focus for future improvement.
Introduction and SLP 3 Context
The SLP 3 scenario yielded relatively poor performance using a strategy that did not deviate significantly from the original scenario. There were, however, a few interesting findings from the cost-volume-profit analysis that can be applied to the strategy employed in SLP 4. Each product is covered in detail below.
X5: Pricing and R&D Strategy
The X5 in 2012 has already been on the market and is probably at or near the top of its product life cycle. It sells good volume and is profitable, but past simulations have shown that the X5 becomes less profitable over time. The X5 carries the highest fixed costs of any product in the portfolio, at $75M, and is expected to drop below the margin of safety by the final year, 2015. By that year, the contribution is expected to fall below fixed costs. Therefore, the X5 should be discontinued after the 2014 year.
There is also the matter of pricing the X5. The original price is currently keeping the X5 profitable. The key decision with respect to pricing is how to set it in a way that extracts the maximum number of sales prior to 2015, at which point the product will be discontinued. Essentially, any potential sales remaining after 2014 represent lost opportunities. However, the trade-off is that lowering the price of the X5 to win those sales will also reduce the per-unit contribution. There is a real risk that lowering the price to increase volume will actually reduce total contribution — lower the price too much, and those additional sales will simply not be worth it.
The other element to consider is R&D funding. The company has a set amount of R&D funding each year — a fixed, organization-wide cost that cannot be changed. However, R&D funding can be divided among the products. More R&D invested in a product increases its desirability in the market. Year-end reports reflect this dynamic through feedback such as "customers feel that this product is priced too high for the features." There is also a one-year lag between when the company invests in R&D and when the benefits of that investment appear in sales. In other words, R&D spending in 2012 does not show on the bottom line until 2013.
For the X5, money invested in R&D in 2012 would show results in 2013 — a point when the product is already peaking. Furthermore, if price is being managed to squeeze out maximum unit sales by 2014, there is no meaningful value in continuing to invest R&D money in this product. R&D dollars directed toward the X5 will not generate a worthwhile return. Therefore, it is recommended that the R&D allocation for the X5 be reduced to zero and those funds be redistributed to the other two products.
The strategy for SLP 4 will therefore set R&D for the X5 to 0% immediately, and lower the price slightly to $270 in order to ensure that as few potential customers as possible remain at the end of 2014.
X6: Premium Product Strategy
The X6 is closer to the beginning of its product life cycle in 2012. It is the company's premium product, which means consumers are generally willing to pay higher prices as long as the features justify them. This has important implications for aligning price with R&D investment. The fixed costs associated with the X6 are $37.5M — exactly half the fixed cost of the X5 — giving this product a considerably higher margin of safety. In fact, upon closer examination, the SLP 3 conclusion that the X6 should be discontinued in 2015 was incorrect. This product will still be profitable at that point and should be continued through 2015.
In terms of pricing, premium product consumers are not particularly price sensitive. They are more driven by features. For that reason, the R&D money freed up from the X5 should be redirected to the X6, ensuring that this product remains competitive at the premium price it commands. The question of whether this reallocation will be sufficient remains open, but if the company can sustain the higher price point, the impact on profits will be positive.
It is therefore recommended that the X6 not be discontinued, that it receive 67% of the total R&D budget, and that its price be maintained throughout the simulation period.
Create your account
Always verify citation format against your institution’s current style guide requirements.